PDF(Pubmed)
Abstract：
UNASSIGNED: The application of sedation and analgesia in spinal anesthesia has many benefits, but the risk of respiratory depression (RD) caused by opioids cannot be ignored. We aimed to observe the effect of dezocine, a partial agonist of μ-receptor, on the median effective dose (ED50) of sufentanil-induced RD in patients undergoing spinal anesthesia combined with low-dose dexmedetomidine.
UNASSIGNED: Sixty-two patients were randomly assigned to dezocine group (DS) and control group (MS). After spinal anesthesia, mask oxygen (5 L/min) and dexmedetomidine (0.1 ug/kg) were given. Five minutes later, patients in the DS group received an Intravenous (IV) bolus of sufentanil and 0.05mg/kg dezocine, while patients in the MS group only received an IV bolus of sufentanil.
UNASSIGNED: ED50 of DS group was 0.342 ug/kg, 95% confidence interval (CI) was (0.269, 0.623) ug/kg, and the ED50 of MS group was 0.291 ug/kg, 95% CI was (0.257, 0.346) ug/kg. There was no difference in the type and treatment measures of RD and hemodynamic changes between the two groups, and no serious adverse reactions occurred in either group.
UNASSIGNED: Dezocine can improve RD induced by sufentanil in patients with spinal anesthesia combined with low-dose dexmedetomidine, and increase the safety window of sufentanil use.
UNASSIGNED: Sixty-two patients were randomly assigned to dezocine group (DS) and control group (MS). After spinal anesthesia, mask oxygen (5 L/min) and dexmedetomidine (0.1 ug/kg) were given. Five minutes later, patients in the DS group received an Intravenous (IV) bolus of sufentanil and 0.05mg/kg dezocine, while patients in the MS group only received an IV bolus of sufentanil.
UNASSIGNED: ED50 of DS group was 0.342 ug/kg, 95% confidence interval (CI) was (0.269, 0.623) ug/kg, and the ED50 of MS group was 0.291 ug/kg, 95% CI was (0.257, 0.346) ug/kg. There was no difference in the type and treatment measures of RD and hemodynamic changes between the two groups, and no serious adverse reactions occurred in either group.
UNASSIGNED: Dezocine can improve RD induced by sufentanil in patients with spinal anesthesia combined with low-dose dexmedetomidine, and increase the safety window of sufentanil use.
摘要：
■镇静镇痛在脊髓麻醉中的应用有很多好处，但阿片类药物引起呼吸抑制（RD）的风险不容忽视。我们的目的是观察地佐辛的效果，μ受体的部分激动剂,舒芬太尼诱导RD的中位有效剂量（ED50）在腰麻联合小剂量右美托咪定中的应用。
■62例患者随机分为地佐辛组（DS）和对照组（MS）。脊髓麻醉后,给予面罩氧气(5L/min)和右美托咪定(0.1ug/kg).五分钟后,DS组患者接受舒芬太尼和0.05mg/kg地佐辛的静脉（IV）推注，而MS组患者仅接受舒芬太尼静脉推注。
■DS组的ED50为0.342ug/kg，95%置信区间(CI)为(0.269,0.623)ug/kg,MS组的ED50为0.291ug/kg，95%CI为(0.257,0.346)ug/kg。两组在RD类型和治疗措施及血流动力学改变方面无差异,两组均未出现严重不良反应。
■地佐辛能改善舒芬太尼复合小剂量右美托咪定腰麻患者的RD，增加舒芬太尼使用的安全窗口。
■62例患者随机分为地佐辛组（DS）和对照组（MS）。脊髓麻醉后,给予面罩氧气(5L/min)和右美托咪定(0.1ug/kg).五分钟后,DS组患者接受舒芬太尼和0.05mg/kg地佐辛的静脉（IV）推注，而MS组患者仅接受舒芬太尼静脉推注。
■DS组的ED50为0.342ug/kg，95%置信区间(CI)为(0.269,0.623)ug/kg,MS组的ED50为0.291ug/kg，95%CI为(0.257,0.346)ug/kg。两组在RD类型和治疗措施及血流动力学改变方面无差异,两组均未出现严重不良反应。
■地佐辛能改善舒芬太尼复合小剂量右美托咪定腰麻患者的RD，增加舒芬太尼使用的安全窗口。
